Literature DB >> 12518117

Intermittent compression pump for nonhealing wounds in patients with limb ischemia. The Mayo Clinic experience (1998-2000).

V M Montori1, S J Kavros, E E Walsh, T W Rooke.   

Abstract

BACKGROUND: The aim of this retrospective observational study was to review the use of an intermittent pneumatic compression device on nonhealing wounds in patients with critical limb ischemia at Mayo Clinic Rochester.
METHODS: The setting was a community and referral multidisciplinary wound care clinic. The authors analysed 107 patients, median age 73, with critical limb ischemia and active ulcers started using a compression device between 1998 and 2000; 101 patients had lower extremity ulcers, and 25% had a history of amputation, and 64% had diabetes. Of all the wounds, 64% were multifactorial in etiology, and 60% had associated transcutaneous oxygen tension levels below 20 mmHg. Patients were typically asked to use the device at home on the affected limb(s) for 6 hours daily. The main outcome criterion was complete wound healing with limb preservation.
RESULTS: The median follow-up after initiation of treatment was 6 months. Complete wound healing with limb preservation was achieved by 40% of patients with TcPO(2) levels below 20 mmHg; by 48% with osteomyelitis or active wound infection; by 46% with diabetes treated with insulin; and by 28% with a previous amputation. Half of all amputations occurred in patients with prior amputations. Seven patients discontinued the device because of pain experienced with its use.
CONCLUSIONS: Patients with critical limb ischemia and nonhealing wounds at high risk of amputation can achieve complete wound healing and limb preservation by using an intermittent pneumatic compression device.

Entities:  

Mesh:

Year:  2002        PMID: 12518117

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  8 in total

1.  Acute impact of intermittent pneumatic leg compression frequency on limb hemodynamics, vascular function, and skeletal muscle gene expression in humans.

Authors:  Ryan D Sheldon; Bruno T Roseguini; John P Thyfault; Brett D Crist; M H Laughlin; Sean C Newcomer
Journal:  J Appl Physiol (1985)       Date:  2012-03-22

Review 2.  Thromboangiitis obliterans.

Authors:  Gregory Piazza; Mark A Creager
Journal:  Circulation       Date:  2010-04-27       Impact factor: 29.690

Review 3.  Critical limb ischemia: current approach and future directions.

Authors:  Kanwar P Singh; Aditya M Sharma
Journal:  J Cardiovasc Transl Res       Date:  2014-05-15       Impact factor: 4.132

Review 4.  Physiology in medicine: peripheral arterial disease.

Authors:  Matthew D Muller; Amy B Reed; Urs A Leuenberger; Lawrence I Sinoway
Journal:  J Appl Physiol (1985)       Date:  2013-08-22

Review 5.  Influence of Comorbidities: Neuropathy, Vasculopathy, and Diabetes on Healing Response Quality.

Authors:  Paul W Ackermann; David A Hart
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-10       Impact factor: 4.730

6.  Acute oxygenation changes on ischemic foot of a novel intermittent pneumatic compression device and of an existing sequential device in severe peripheral arterial disease.

Authors:  Fabio Manfredini; Anna Maria Malagoni; Michele Felisatti; Simona Mandini; Nicola Lamberti; Roberto Manfredini; Francesco Mascoli; Nino Basaglia; Paolo Zamboni
Journal:  BMC Cardiovasc Disord       Date:  2014-03-31       Impact factor: 2.298

7.  Improving Limb Salvage for Chronic Limb-Threatening Ischemia With Spinal Cord Stimulation: A Retrospective Analysis.

Authors:  Anna E Cyrek; Nora Henn; Fabian Meinhardt; Martin Lainka; Arkadius Pacha; Andreas Paul; Dietrich Koch
Journal:  Vasc Endovascular Surg       Date:  2021-02-08       Impact factor: 1.089

8.  The long-term arterial assist intermittent pneumatic compression generating venous flow obstruction is responsible for improvement of arterial flow in ischemic legs.

Authors:  Marzanna T Zaleska; Waldemar L Olszewski; Jonathan Ross
Journal:  PLoS One       Date:  2019-12-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.